Crinetics Pharmaceuticals (CRNX)
Develops oral GPCR medicines for endocrine diseases and endocrine-related tumors.
$84.95
0.00 (0.00%)
Delisted · Sep 2, 2026
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 117.04% | 124.14M shares | |
|---|---|---|---|
| 273 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.21% | 1.28M shares | |
| 5 holders · as of Sep 1, 2026 | |||
| Adds to | 118.25% | ||
106.07M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 118.25%; nothing is left for Other.
13F, as of Jun 30, 2026
273 holders · 124.14M shares · 59 new positions · 158 increased · 70 reduced · 33 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 15.84M | 14.93% | +80.4K | Aug 13, 2026 |
| BlackRock, Inc. | 9.76M | 9.20% | +1.28M | Aug 7, 2026 |
| Farallon Capital Management LLC | 8.99M | 8.48% | +651.0K | Aug 14, 2026 |
| Wellington Management Group LLP | 7.13M | 6.72% | −1.03M | Aug 14, 2026 |
| Driehaus Capital Management LLC | 6.46M | 6.09% | +67.6K | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.21M | 5.86% | +857.2K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 4.83M | 4.56% | +194.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.75M | 4.47% | +71.3K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 13.96M | 13G | May 12, 2025 |
| Wellington Management Group LLP | 7.80% | 8.16M | 13G | May 15, 2026 |
| Driehaus Capital Management LLC | 6.11% | 6.40M | 13G | May 15, 2026 |
| Wellington Investment Advisors Holdings LLPincl. Wellington Management Group LLP, Wellington Group Holdings LLP +1 more | 5.57% | 4.46M | 13G | Nov 8, 2024 |
| Vanguard Capital Management | 5.19% | 5.44M | 13G | Apr 29, 2026 |
| T. Rowe Price Associates, Inc. | 5.10% | 5.36M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 2, 2026 | Coelho Rogerio Vivaldidirector | Sale | 3,000 | $40.00 | 19,225 |
| Jun 17, 2026 | Stephanie Okeydirector | Sale · 2 lots | 6,900 | $35.67 | 6,400 |
| Apr 8, 2026 | Jeff E. Knightofficer: Chief Dev. & Operating Officer | Sale | 85,163 | $40.10 | 105,289 |
| Mar 16, 2026 | Richard Scott Struthersdirector, officer: President & CEO | Sale · 2 lots | 21,981 | $37.37 | 404,778 |
| Mar 16, 2026 | Stephen F. Betzofficer: Chief Scientific Officer | Sale · 2 lots | 10,612 | $37.37 | 137,101 |
| Mar 16, 2026 | Jeff E. Knightofficer: Chief Operating Officer | Sale · 2 lots | 9,911 | $37.37 | 112,018 |
| Mar 12, 2026 | Coelho Rogerio Vivaldidirector | Sale · 2 lots | 5,000 | $36.15 | 16,300 |
| Mar 3, 2026 | Tobin Schilkeofficer: Chief Financial Officer | Sale | 6,713 | $39.67 | 78,121 |
| Mar 3, 2026 | Stephanie Okeydirector | Sale | 3,000 | $39.67 | 13,300 |
| Jan 5, 2026 | Isabel Kalofonosofficer: Chief Commercial Officer | Sale | 2,500 | $55.00 | 834 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Gilbert Cisneros · CA31 | Sale | $15,001 – $50,000 | Jul 30, 2026 | Sep 7, 2026 | |
| Rep. Gilbert Ray Cisneros · CA31 | Sale (Full) | $15,001 – $50,000 | Jul 30, 2026 | Sep 7, 2026 | |
| Rep. Gilbert Ray Cisneros · CA31 | Sale (Full) | $15,001 – $50,000 | Jul 29, 2026 | Sep 7, 2026 |